Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...

For the better part of a year, Merck & Co. and Halozyme have been locked in an intellectual property disagreement over the the pharma giant's new, under-the-skin version of cancer megablockbuster ...